Cerus Corporation announced that its chief operating officer, Vivek Jayaraman, will become president and chief executive officer effective July 1, 2026. William “Obi” Greenman will transition to executive chairman of the board and join the board of directors.
Jayaraman, who has led Cerus’s commercial operations for several years, will bring his experience in scaling the INTERCEPT blood‑safety platform to the CEO role. Greenman, who has served as CEO since 2018, will focus on strategic oversight as executive chairman.
Cerus’s core business remains the INTERCEPT platform, a single‑segment blood‑safety solution that has driven product revenue to $206.1 million in 2025, a 14 % increase from $180.5 million in 2024. The fourth‑quarter 2025 product revenue of $57.8 million also rose 14 % YoY, while the company’s net loss narrowed to $2.2 million from $2.5 million in the same quarter of 2024. The company reaffirmed its 2026 product revenue guidance, underscoring confidence in continued growth.
Frank Witney, lead independent director, said, “Following a thorough succession planning process, this transition represents a natural step as we prepare for the next phase of growth at Cerus.” Jayaraman added, “I’m honored to lead Cerus, in partnership with our exceptional employees, during this exciting next chapter. We will broaden patient access to the INTERCEPT Blood System globally, expand our leadership in transfusion medicine, and improve patient outcomes. I am very grateful to Obi and the Cerus Board of Directors for entrusting me with this extraordinary opportunity to serve.” Obi Greenman noted, “I am proud of the progress Cerus has made in advancing blood safety and availability. Having worked with Vivek for nearly a decade, I am confident that he is the right person to lead Cerus towards the goal of making INTERCEPT the global standard of care.”
The leadership transition is part of a broader strategy to accelerate the rollout of the INTERCEPT Fibrinogen Complex kit and the development of the INTERCEPT Red Blood Cell system, which is in late‑stage clinical development in the U.S. and under regulatory review in Europe. Cerus also continues to expand access through a group purchasing agreement with Blood Centers of America, covering roughly half of the U.S. blood supply, and has secured a BARDA contract supporting the Red Blood Cell system’s development.
With Jayaraman at the helm, Cerus aims to sustain its revenue momentum while deepening its market share in transfusion medicine. The company’s single‑segment focus on blood safety positions it to capitalize on growing demand for pathogen‑inactivated blood products, and the reaffirmed guidance signals management’s confidence in the platform’s commercial trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.